Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care

J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S1-53. doi: 10.18553/jmcp.2013.19.s1.1.
No abstract available

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / therapeutic use
  • Humans
  • Injections, Intramuscular
  • Interferon beta-1a
  • Interferon-beta / administration & dosage*
  • Interferon-beta / therapeutic use*
  • Managed Care Programs*
  • Multiple Sclerosis / drug therapy*
  • Outcome Assessment, Health Care

Substances

  • Adjuvants, Immunologic
  • Interferon-beta
  • Interferon beta-1a